Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Smith, Danielle G. | Ciccotosto, Giuseppe D. | Tew, Deborah J. | Perez, Keyla | Curtain, Cyril C. | Boas, John F. | Masters, Colin L. | Cappai, Roberto | Barnham, Kevin J.
Article Type: Research Article
Abstract: Amyloid-β peptide (Aβ) toxicity is thought to be responsible for the neurodegeneration associated with Alzheimer's disease. While the mechanism(s) that modulate this toxicity are still widely debated, it has previously been demonstrated that modifications to the three histidine residues (6, 13, and 14) of Aβ are able to modulate the toxicity. Therefore to further elucidate the potential role of the histidine (H) residues in Aβ toxicity, we synthesized Aβ peptides with single alanine substitutions for each of the three histidine residues and ascertained how these substitutions affect peptide aggregation, metal binding, redox chemistry, and cell membrane interactions, factors which have …previously been shown to modulate Aβ toxicity. Aβ42 H13A and Aβ42 H6A modified peptides were able to induce significant cell toxicity in primary cortical cell cultures at levels similar to the wild-type peptide. However, Aβ42 H14A did not induce any measurable toxicity in the same cultures. This lack of toxicity correlated with the inability of the Aβ42 H14A to bind to cell membranes. The interaction of Aβ with cell membranes has previously been shown to be dependent on electrostatic interactions between Aβ and the negatively charged head group of phosphatidylserine. Our data suggests that it is the imidazole sidechain of histidine 14 that modulates this interaction and strategies inhibiting this interaction may have therapeutic potential for Alzheimer's disease. Show more
Keywords: Amyloid, cell membrane, neurotoxicity, phosphatidylserine
DOI: 10.3233/JAD-2010-1334
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1387-1400, 2010
Authors: Koedam, Esther L.G.E. | Lauffer, Vivian | van der Vlies, Annelies E. | van der Flier, Wiesje M. | Scheltens, Philip | Pijnenburg, Yolande A.L.
Article Type: Research Article
Abstract: Alzheimer's disease (AD) is the most common cause of dementia at older age. Although less prevalent before the age of 65 years, it is still the most frequent cause of early-onset dementia followed by frontotemporal dementia. The typical presentation of AD is memory dysfunction, however, presentations with prominent cognitive impairment in other domains besides memory, like prominent apraxia, language problems, or executive dysfunction, may occur and are relatively more common in early-onset AD. In this retrospective descriptive study, we determined the prevalence of non-memory presentations in a large sample of early-onset AD patients compared to late-onset AD. The clinical files …of 270 patients with AD starting before the age of 65 years and 90 patients with late-onset AD (⩾ 65 years) were reviewed to assess clinical characteristics. Patients were classified as memory presentation and non-memory presentation according to their clinical presentation. The mean age of the early-onset group was 56 ± 5 years and 74 ± 6 years for the late-onset group. A third of the early-onset AD group presented with non-memory symptoms compared to only 6% in the late-onset group (p < 0.001). Within the group with non-memory presentations, apraxia/visuospatial dysfunction was the most prevalent presenting symptom (12%). Patients with early-onset AD often present with a non-memory phenotype, of which apraxia/visuospatial dysfunction is the most common presenting symptom. Atypical presentations of AD should be considered in the clinical differential diagnosis of early-onset dementia. Show more
Keywords: Alzheimer's disease, clinical presentation, dementia, early onset
DOI: 10.3233/JAD-2010-1337
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1401-1408, 2010
Authors: Dance, Amber | Landhuis, Esther | Strobel, Gabrielle
Article Type: Editorial
DOI: 10.3233/JAD-2010-1323
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1409-1415, 2010
Article Type: Announcement
DOI: 10.3233/JAD-2010-1327
Citation: Journal of Alzheimer's Disease, vol. 19, no. 4, pp. 1417-1419, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl